Histopathological and molecular characteristics of IDH-wildtype glioblastoma without contrast enhancement: Implications for clinical outcomes
Neuro-Oncology · 08.09.2025 · 27 (7) · 1878-1887
DOI: 10.1093/neuonc/noaf070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 20.03.2025. Verfasst von Martha Foltyn-Dumitru und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division for Computational Radiology & Clinical AI, Bonn University Hospital, Bonn, Germany. Hauptthemen laut MEDLINE: Glioblastoma, Isocitrate Dehydrogenase, Brain Neoplasms, Mutation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: AI Health Innovation Cluster of the Heidelberg-Mannheim Health and Life Science Alliance, Heidelberg University, Faculty of Medicine, Else Kröner Research College for Young Scientist.
Abstract (Originalsprache)
Background
Glioblastoma (GB) heterogeneity poses substantial challenges for diagnosis and treatment. Isocitrate dehydrogenase (IDH)-wildtype GB may lack contrast enhancement on MRI and exhibit a “low-grade radiologic appearance” (non-contrast-enhancing [CE] GB), a phenomenon with unclear clinical implications. This study investigates the histopathological and molecular differences and survival outcomes between CE and non-CE GB.
Methods
This retrospective study at Heidelberg University Hospital analyzed 457 IDH-wildtype GB cases (09/2009–01/2021). Contrast enhancement on preoperative MRI was volumetrically assessed, classifying tumors as non-CE/CE GB using a 1 cm³ cutoff. Molecular and histopathological features, including microvascular proliferation, necrosis, and overall survival (OS), were compared between the groups.
Results
Of the initial cohort, 352 (77%) patients met the inclusion criteria, with 44 (12.5%) non-CE and 308 (87.5%) CE GB. The histopathological assessment revealed that non-CE GB was less likely to present traditional hallmarks of GB, such as microvascular proliferation (39% vs. 94%) and necrosis (25% vs. 92%) (P < .001). In the non-CE group, 24 patients (55%) were diagnosed as molecular GB, compared to only 8 patients (3%) in the CE group (P < .001). A significant difference was observed in Ki-67 levels, with non-CE GBs having a lower mean Ki-67 index of 18% ± 12% compared to 26% ± 13% in CE tumors (P < .001). The median OS was 27.2 months (95% CI, 19.8–NA) for non-CE and 14.7 months (95% CI, 13.2–17.1) for CE GB (P = .0049).
Conclusions
IDH-wildtype GBs without contrast enhancement are often diagnosed based on molecular criteria due to less frequent histopathological hallmarks and are associated with prolonged OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division for Computational Radiology & Clinical AI, Bonn University Hospital, Bonn, Germany.
- Department of Neuroradiology, Bonn University Hospital, Bonn, Germany.
- Division for Computational Neuroimaging, Heidelberg University Hospital, Heidelberg, Germany.
- Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
- Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany.
- Department of Radiology and Nuclear Medicine, Diagnostic and Interventional Neuroradiology, University Hospital Basel, University of Basel, Basel, Switzerland.
ORCID-Profile: Tobias Kessler, Martin Bendszus, Felix Sahm, Philipp Vollmuth
Förderung
- AI Health Innovation Cluster of the Heidelberg-Mannheim Health and Life Science Alliance
- Heidelberg University, Faculty of Medicine
- Else Kröner Research College for Young Scientist
- Else Kröner Fresenius Foundation
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Foltyn-Dumitru, M., Banan, R., Schell, M., Mahmutoglu, M. A., Kessler, T., Wick, W., Brugnara, G., Bendszus, M., Sahm, F., & Vollmuth, P. (2025). Histopathological and molecular characteristics of IDH-wildtype glioblastoma without contrast enhancement: Implications for clinical outcomes. Neuro-Oncology, 27(7), 1878-1887. https://doi.org/10.1093/neuonc/noaf070
Vancouver
Foltyn-Dumitru M, Banan R, Schell M, Mahmutoglu MA, Kessler T, Wick W, et al. Histopathological and molecular characteristics of IDH-wildtype glioblastoma without contrast enhancement: Implications for clinical outcomes. Neuro-Oncology. 2025;27(7):1878-1887. doi:10.1093/neuonc/noaf070
BibTeX
@article{FoltynDumitru2025,
author = {Foltyn-Dumitru, Martha and Banan, Rouzbeh and Schell, Marianne and Mahmutoglu, Mustafa Ahmed and Kessler, Tobias and Wick, Wolfgang and Brugnara, Gianluca and Bendszus, Martin and Sahm, Felix and Vollmuth, Philipp},
title = {Histopathological and molecular characteristics of IDH-wildtype glioblastoma without contrast enhancement: Implications for clinical outcomes},
journal = {Neuro-Oncology},
year = {2025},
volume = {27},
number = {7},
pages = {1878--1887},
doi = {10.1093/neuonc/noaf070}
}
EUVIMED